Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
The guidance provides the agency's thoughts on the emerging use of ctDNA residual disease testing to select patients for treatment in trials of new adjuvant therapies.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
CMS Final Pricing for Genomic Procedure Codes Leaves Lab, Industry Stakeholders Wanting More
Premium
After going through the gapfill process and releasing final pricing for six codes related to genomic sequencing procedures, the final pricing still has stakeholders worried.
According to the company, its work with organoids and mouse models of Alzheimer's disease has detected roughly 800 proteoforms of the protein tau.
Mursla Bio, a Cambridge, UK-based company that focuses on EV isolation, biomarker discovery from EV cargo, and EV assays for clinical use, is an EVEREST participant.
Cerebral Palsy Sequencing Study Finds Clinically Actionable Alterations
Researchers trawled exome sequencing data to identify clinically actionable variants in 8 percent of cerebral palsy patients tested.
GenomeWeb Top 40 Rises 3 Percent in November Amidst Mixed Broader Market
In comparison, the Dow Jones Industrial Average rose 8 percent and the Nasdaq rose 6 percent, but the Nasdaq Biotech Index was in negative territory, falling by less than 1 percent.